Background: Nitroglycerin (NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia-inducible-factor (HIF)-1. A randomized phase II study has shown improved outcome when NTG patches were added to vinorelbine/cisplatin in patients with advanced nonsmall-cell lung cancer (NSCLC). In addition, there is evidence that the combination of bevacizumab and HIF-1 inhibitors increases antitumor activity.
Patients And Methods: In this randomized phase II trial, chemo-naive patients with stage IV nonsquamous NSCLC were randomized to four cycles of carboplatin (area under the curve 6)-paclitaxel (200 mg/m(2))-bevacizumab 15 mg/kg on day 1 every 3 weeks with or without NTG patches 15 mg (day -2 to +2) followed by bevacizumab with or without NTG until progression. Response was assessed every two cycles. Primary end point was progression-free survival (PFS). The study was powered (80%) to detect a decrease in the hazard of tumor progression of 33% at α = 0.05 with a two-sided log-rank test when 222 patients were enrolled and followed until 195 events were observed.
Results: Between 1 January 2011 and 1 January 2013, a total of 223 patients were randomized; 112 control arm and 111 experimental arm; response rate was 54% in control arm and 38% in experimental arm. Median [95% confidence interval (CI)] PFS in control arm was 6.8 months (5.6-7.3) and 5.1 months (4.2-5.8) in experimental arm, hazard ratio (HR) 1.27 (95% CI 0.96-1.67). Overall survival (OS) was 11.6 months (8.8-13.6) in control arm and 9.4 months (7.8-11.3) in experimental arm, HR 1.02 (95% CI 0.71-1.46). In the experimental arm, no additional toxicity was observed except headache (6% versus 52% in patients treated with NTG).
Conclusion: Adding NTG to first-line carboplatin-paclitaxel-bevacizumab did not improve PFS and OS in patients with stage IV nonsquamous NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/mdv370 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Generalizing the intention-to-treat effect of an active control from historical placebo-controlled trials: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study.
J Am Stat Assoc
July 2024
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center.
In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control (e.
View Article and Find Full Text PDFSurface electromyography vs clinical outcome measures after robot-assisted gait training in patients with spinal cord injury after post-acute phase of rehabilitation.
Ann Agric Environ Med
December 2024
Department of Rehabilitation, Medical University of Warsaw, Warsaw, Poland.
Introduction And Objective: Surface electromyography (sEMG) measurements are a valid method for sublesional muscle activity following spinal cord injury (SCI). In the literature there are few reports evaluating the effect of robotic assisted gait training (RAGT) on the sEMG properties change in SCI patients. The aim of this study was to evaluate the influence of RAGT on observed change of sEMG, and in 64 incomplete SCI patients in the sub-acute stage in relation to functional scales.
View Article and Find Full Text PDFChemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis.
Semin Oncol
December 2024
Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Torino, Italy.
Background: Small-cell lung cancer (SCLC) accounts for 10%-15% of all lung cancers. At diagnosis, nearly two thirds of patients with SCLC have extensive stage (ES), with a median overall survival (OS) less than 12 months. The combination of protein-death-1/protein-death-ligand-1 (PD-1/PD-L1) immune checkpoint inhibitors (ICIs) with first-line platinum plus etoposide chemotherapy has changed the therapeutic landscape for ES-SCLC.
View Article and Find Full Text PDFUnveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.
Biol Direct
December 2024
Urology Unit, Department of Surgery, Tor Vergata University of Rome, Rome, Italy.
Background: Prostate cancer is the most common diagnosed tumor and the fifth cancer related death among men in Europe. Although several genetic alterations such as ERG-TMPRSS2 fusion, MYC amplification, PTEN deletion and mutations in p53 and BRCA2 genes play a key role in the pathogenesis of prostate cancer, specific gene alteration signature that could distinguish indolent from aggressive prostate cancer or may aid in patient stratification for prognosis and/or clinical management of patients with prostate cancer is still missing. Therefore, here, by a multi-omics approach we describe a prostate cancer carrying the fusion of TMPRSS2 with ERG gene and deletion of 16q chromosome arm.
View Article and Find Full Text PDFInterpretable machine learning models reveal the partnership of microplastics and perfluoroalkyl substances in sediments at a century scale.
J Hazard Mater
December 2024
School of Environment, Nanjing Normal University, Nanjing 210023, China; Jiangsu Province Engineering Research Center of Environmental Risk Prevention and Emergency Response Technology, Nanjing 210023, China. Electronic address:
It is challenging to explore the complex interactions between perfluoroalkyl substances (PFASs) and microplastics in lake sediments. The partnership of perfluoroalkyl substances (PFASs) and microplastics in lake sediments are difficult to determine experimentally. This study utilized sediment cores from Taihu Lake to reconstruct the coexistence history and innovatively reveal the collaboration between PFASs and microplastics by using post-hoc interpretable machine learning methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!